anastrozole has been researched along with Lassitude in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy." | 7.81 | Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. ( Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A, 2015) |
| "Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy." | 3.81 | Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. ( Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A, 2015) |
| ", tamoxifen and anastrozole) on cognitive functioning by comparing 28 postmenopausal women with breast cancer to 37 healthy age-equivalent controls." | 3.76 | Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer. ( Crossley, M; Lejbak, L; Vrbancic, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mao, JJ | 1 |
| Farrar, JT | 1 |
| Bruner, D | 1 |
| Zee, J | 1 |
| Bowman, M | 1 |
| Seluzicki, C | 1 |
| DeMichele, A | 1 |
| Xie, SX | 1 |
| Shankar, A | 1 |
| Roy, S | 1 |
| Rath, GK | 1 |
| Julka, PK | 1 |
| Kamal, VK | 1 |
| Malik, A | 1 |
| Patil, J | 1 |
| Jeyaraj, PA | 1 |
| Mahajan, MK | 1 |
| Lejbak, L | 1 |
| Vrbancic, M | 1 |
| Crossley, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study (CONCEPT Trial)[NCT04012918] | Phase 2 | 124 participants (Anticipated) | Interventional | 2018-08-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for anastrozole and Lassitude
| Article | Year |
|---|---|
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Topics: Aged; Anastrozole; Androstadienes; Anxiety; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Depr | 2014 |
2 other studies available for anastrozole and Lassitude
| Article | Year |
|---|---|
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Brea | 2015 |
Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Estrogen Antagonists | 2010 |